Task: Question Generation
Input (English): Maternal-fetal transfer of docosahexaenoic acid (DHA) is impaired by gestational diabetes mellitus (GDM), but the underlying mechanisms are still unknown. MFSD2a was recently recognized as a lyso-phospholipid (lyso-PL) transporter that facilitates DHA accretion in brain. The role of this transporter in placenta is uncertain. We evaluated effects of GDM and its treatment (diet or insulin) on phospholipid species, fatty acid profile in women, cord blood and placental fatty acid carriers.', 'Prospective observational study of pregnant women recruited in the third trimester (25 controls, 23 GDM-diet, 20 GDM-insulin). Fetal ultrasound was performed at gestational week 38. At delivery, maternal and neonatal anthropometry was performed, and fatty acids in total lipids and phospholipid species were analyzed in placenta, maternal and venous cord blood. Western-blot analyses were performed for placental fatty acid carriers.', 'Fetal abdominal circumference z-score at 38 weeks tended to higher values in GDM (P\xa0=\xa00.071), pointing toward higher fetal fat accretion in these babies. DHA percentage in cord serum total lipids (P\xa0=\xa00.029) and lyso-PL (P\xa0=\xa00.169) were reduced in GDM. Placental MFSD2a was reduced in both GDM groups and was positively correlated to DHA values in cord serum total lipids (r\xa0=\xa00.388, P\xa0=\xa00.003). Among established placental lipid carriers, only FATP4 was correlated to DHA concentration in placental lyso-PL. In all compartments, DHA percentage was inversely correlated to fetal abdominal circumference.
Output (English): Is placental MFSD2a transporter related to decreased DHA in cord blood of women with treated gestational diabetes?